Novartis Consolidates MorphoSys’s Pioneering Work
The story of MorphoSys illustrates just how painful the path from discovery to market readiness can be. Over decades, this Munich-based flagship company demonstrated how to rise to become an indispensable partner of the global pharmaceutical elite through antibody libraries. But MorphoSys also proves that developing new active ingredients devours billions and carries enormous clinical risks. The USD 2.9 billion acquisition by Novartis underscores that, in the end, it is often the deep pockets of the major players that determine which innovator ultimately survives.
Novartis itself has consistently evolved into a pure-play in innovative drugs. The company reported net sales of USD 13.1 billion for the first quarter, exceeding market expectations. Despite the looming patent cliff, analysts consider the ambitious targets for key drugs to be realistic. The Basel-based company’s strategy is to tap into new platforms for complex therapies through targeted acquisitions and strategic partnerships, thereby securing its long-term market position.
BioNTech: Disruption Through Platform Logic
The Mainz-based company BioNTech took a different path to disruption. Through mRNA technology, BioNTech has proven that it is not a single active ingredient, but a platform technology that can change the world. Here, mRNA acts as a digital code that instructs the body to produce the “remedy” itself. But challenges arise here as well: even the best mRNA instructions require a highly complex transport system to become effective in the body.
Without the perfect interface of lipid nanoparticles between the code and the cell, any innovation remains ineffective. Mastering this transport system is BioNTech’s true technological moat. The company aims to become a fully integrated oncology company by 2030 and plans to have a large number of active studies in the crucial Phase 3 by the end of 2026. With a cash position of nearly EUR 16.8 billion, BioNTech is largely low-risk in terms of financing its broad research agenda and can respond agilely to market opportunities.
BioNxt Solutions Conquers the Last Mile
Small-cap company BioNxt Solutions is positioning itself in a strategically promising niche. While MorphoSys focused on new molecules until its acquisition by Novartis and BioNTech leverages the genetic code, BioNxt focuses on the “last mile” of treatment. The company recognizes that the effectiveness of a therapy depends largely on how the active ingredient is administered and how well the patient can integrate this application into their daily routine. Using ODF (Oral Dissolvable Films) technology, BioNxt transforms complex active ingredients into wafer-thin sublingual melt films.
These films dissolve under the tongue within seconds and release the active ingredient directly into the bloodstream via the oral mucosa, bypassing the gastrointestinal tract and enabling significantly higher bioavailability. The key advantage for investors: BioNxt reduces clinical risk by re-launching already approved blockbuster drugs using a superior delivery form. A breakthrough was achieved with the flagship program BNT23001, a sublingual cladribine formulation for the treatment of multiple sclerosis. Studies demonstrated approximately 40% higher drug absorption than with the conventional tablet form, representing an enormous improvement in quality of life for patients with swallowing difficulties.
Strategic Lifecycle Management Against the Patent Cliff
While pharmaceutical giants like Novartis seek ways to protect their patents from expiring, BioNxt offers the solution. A new, patented ODF formulation of an off-patent active ingredient enables the original manufacturer to defend market share with a new, superior product. The granting of the European patent for the sublingual cladribine technology in February proves that BioNxt’s strategy is paying off.
The developments surrounding Novartis, BioNTech, and BioNxt Solutions demonstrate that while many investors are betting on the next “lucky punch” in drug discovery, the more predictable leverage lies in platforms that improve the usability of existing active ingredients. These active ingredients are increasingly viewed as mere raw materials—the real value lies in the “how” of administration. As clinical validation continues to advance, BioNxt is therefore regarded by specialized market observers as an attractive potential acquisition target. Investors who see opportunities in the trend toward more efficient drug delivery are positioning themselves in BioNxt shares.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.